This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Granulomas  • Rheumatology  • Osteoporosis  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Cheryl Groves, MB, MRCPE; Mairin E. McMenamin, MB, MRCPI, FRCPath; Maureen Casey, MB, MRCPI; Louise Barnes, MD, FRCPI

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We report herein the novel occurrence of an interstitial granulomatous drug reaction in response to treatment with strontium ranelate, an anabolic skeletal agent used to treat postmenopausal osteoporosis.

Report of a Case

A 54-year-old white woman presented with a 7-month history of nontender, nonpruritic, erythematous, violaceous patches and plaques affecting axillae, upper arms, wrists, and medial thighs (Figure 1). Treatment with strontium ranelate and calcium supplements had commenced 10 months earlier, and the patient was taking no other medications. Apart from osteoporosis, she denied any previous medical problems. Results of routine blood tests, including glucose tests, were normal. Autoantibodies were undetectable.

Figure appears in full text version. Figure 1. Subtle erythematous plaques extending from axilla to upper arm.

Skin biopsy specimens revealed foci of histiocytes and occasional plasma cells distributed interstitially throughout the reticular dermis associated with degenerate eosinophilic collagen . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION